Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA), Saxenda (liraglutide), and Pernix’s (formerly Orexigen’s) Contrave designed to reduce food intake, dominated the obesity market in 2016, generating $215M and $214M in the US, respectively. Multiple pharma developers are investigating long-acting GLP-1RAs, dual GLP-1R/glucagon receptor (GCGR) agonists, and tri-agonists targeting GLP-1R, GCGR, and gastric inhibitory polypeptide receptor (GIPR), which will contribute to the future growth of the obesity market. GlobalData identified Novo Nordisk as the strongest industry player, with 40 sponsored obesity clinical trials, followed by Sanofi (26) and AstraZeneca (20).

Obesity is a preventable chronic condition characterised by raised body mass index (BMI ≥30), which contributes to the pathogenesis of cardiovascular diseases, type 2 diabetes (T2D), musculoskeletal disorders, and several major cancers. Obesity has become an epidemic and it is recognised as one of the major health issues due to its associated high rates of morbidity, mortality, and health cost. Over 1.9 billion people were overweight or obese worldwide in 2016; of these, over 34% (650 million) were obese. Obesity is most prevalent in the US among the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) with an estimated 97 million people in 2016, according to GlobalData epidemiologists.

Nevertheless, the current obesity market is rather sparse, with GlaxoSmithKline’s/Roche’s lipase inhibitor, Orlistat, being the only approved product for the treatment of obesity, before Eisai and Vivus entered the US obesity space with their appetite-regulating drugs Belviq (lorcaserin hydrochloride) and Qsymia (phentermine hydrochloride + topiramate), respectively, in 2012. The US has the largest number of approved drugs while Japan has the fewest; Takeda’s Oblean (cetilistat) lipase inhibitor is the only approved anti-obesity drug in Japan.

Today, obesity is the third most investigated indication within the metabolic disorders therapy area, which includes 253 products across all indications and stages of clinical development across the 8MM. GLP-1R–targeting molecules, primarily used in T2D to improve glucose homeostasis, are a major focus of obesity drug developers due to their added benefit of reducing weight, even though resultant weight loss can vary considerably between individuals. Therefore, new targets, including GCGR, cannabinoid receptor 1 (CNR1), GIPR, melanocortin-4 receptor (MC4R), serotonin receptor 2C (HTR2C), AMP-activated protein kinase (AMPK), calcitonin receptor (CALCR), leptin receptor (LEPR), and islet amyloid polypeptide (IAPP) are also drawing drug developers’ attention.

Figure 1 presents the top targets for drug development against obesity.

Figure 1: top targets for drug development against obesity

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

View profiles in store

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Submit

UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData expects that Novo Nordisk will remain a strong player in the obesity space for the next 10 years. This is due to the company’s marketed GLP-1 analog, Saxenda, and a long-acting (once weekly) GLP-1 analog, semaglutide, which will be the first to market among the new-generation GLP-1RAs in the obesity space—around the same time as its daily injectable’s patent expires in 2022. Sanofi and Hanmi also have a long-acting (once weekly) GLP-1RA in development, efpeglenatide, which will launch in competition with Novo Nordisk’s GLP-1RA approximately one year later, in 2023.

AstraZeneca’s/MedImmune’s MEDI-0382, Sanofi’s SAR425899, and OPKO Health’s OPK-88003 dual GLP-1R/GCGR agonists are also likely to launch from 2023, and as a result, the US obesity space will become crowded with new-generation GLP-1R–targeting drugs by 2026. Additionally, a first-in-class anti-obesity drug, Rhythm’s setmelanotide, which reduces appetite and increases energy expenditure in obesity due to rare genetic disorders—genetic variations within the MC4 pathway associated with unrelenting hunger—will also enter the US obesity market in 2023. In China, Novo Nordisk will be the only company launching a drug (semaglutide) for the treatment of obesity, despite China having the second highest prevalence of obesity in the 8MM. Overall, GlobalData’s research shows that the obesity market is about to expand, particularly in the US and the 5EU (France, Germany, Italy, Spain, and the UK).

GlobalData expects that the launches of the new anti-obesity drugs will bring a marked change from 2022 in the otherwise slowly developing obesity market.